MorphoSys is a late-stage, biopharmaceutical company devoted to the development of therapies for patients suffering from serious diseases. The company’s most advanced proprietary product candidate, MOR208, received FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory DLBCL. Based on its leadership in generating antibodies, MorphoSys, together with its partners, has developed more than 100 product candidates of which 29 are currently in clinical development.